Publications
ShareCompartir
Morbidity and Mortality Weekly Report (MMWR)
- Two cases of visceral leishmaniasis in U.S. military personnel—Afghanistan, 2002–2004 (April 2, 2004 / 53(12);265-268)
- Update: cutaneous leishmaniasis in U.S. military personnel—Southwest/Central Asia, 2002–2004 (April 2, 2004 / 53(12);264-265)
- Cutaneous leishmaniasis in U.S. military personnel—Southwest/Central Asia, 2002–2003 (October 24, 2003 / 52(42);1009-1012)
- Unexplained illness among Persian Gulf War veterans in an Air National Guard Unit: preliminary report — August 1990-March 1995 (June 16, 1995 / 44(23);443-447)
- Viscerotropic leishmaniasis in persons returning from Operation Desert Storm — 1990 – 1991 (February 28, 1992 / 41(08);131-134)
Emerging Infectious Diseases (EID)
- Hussain M, Munir S, Khan TA, et al. Epidemiology of cutaneous leishmaniasis outbreak, Waziristan, Pakistan. Emerg Infect Dis 2018;24:159-61.
- Polley SD, Watson J, Chiodini PL, Lockwood DNJ. Visceral leishmaniasis in traveler to Guyana caused by Leishmania siamensis, London, UK. Emerg Infect Dis 2018;24:155-6.
- Al-Salem WS, Pigott DM, Subramaniam K, et al. Cutaneous leishmaniasis and conflict in Syria. Emerg Infect Dis 2016;22:931-3.
- Monteiro DC, Sousa AQ, Lima DM, et al. Leishmania infantum infection in blood donors, northeastern Brazil. Emerg Infect Dis 2016;22:739-40.
- Schaut RG, Robles-Murguia M, Juelsgaard R, et al. Vectorborne transmission of Leishmania infantum from hounds, United States. Emerg Infect Dis 2015;21:2209-12.
- Saroufim M, Charafeddine K, Issa G, et al. Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon. Emerg Infect Dis 2014;20:1712-5.
- Gandacu D, Glazer Y, Anis E, et al. Resurgence of cutaneous leishmaniasis in Israel, 2001—2012. Emerg Infect Dis 2014;20:1605-11.
- Cojean S, Houzé S, Haouchine D, et al. Leishmania resistance to miltefosine related to genetic marker [letter]. Emerg Infect Dis 2012;18:704-6.
- Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg Infect Dis 2009;15:956-9.
- Gangneux JP, Sauzet S, Donnard S, et al. Recurrent American cutaneous leishmaniasis [letter]. Emerg Infect Dis 2007;13:1436-8.
- Nawaratna SS, Weilgama DJ, Wijekoon CJ, Dissanayake M, Rajapaksha K. Cutaneous leishmaniasis, Sri Lanka. Emerg Infect Dis 2007;13:1068-70.
- Siriwardana HV, Noyes HA, Beeching NJ, Chance ML, Karunaweera ND, Bates PA. Leishmania donovani and cutaneous leishmaniasis, Sri Lanka. Emerg Infect Dis 2007;13:476-8.
- Faulde MK, Heyl G, Amirih ML. Zoonotic cutaneous leishmaniasis, Afghanistan [letter]. Emerg Infect Dis 2006;12:1623-4.
- Boehme CC, Hain U, Novosel A, Eichenlaub S, Fleischmann E, Loscher T. Congenital visceral leishmaniasis [letter]. Emerg Infect Dis 2006;12:359-60.
- Duprey ZH, Steurer FJ, Rooney JA, et al. Canine visceral leishmaniasis, United States and Canada, 2000–2003. Emerg Infect Dis 2006;12:440-6.
Other References
- World Health Organization. Global leishmaniasis update, 2006–2015: a turning point in leishmaniasis surveillance. Wkly Epidemiol Rec 2017;92:557-65.
- Heras-Mosteiro J, Monge-Maillo B, Pinart M, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2017;12:CD005067.
- Herwaldt BL. Protozoa and helminths. In Wooley DW, Byers KB (eds.). Biological Safety: Principles and Practices. 5th ed. Washington, DC: American Society for Microbiology, 2017:105-45.
- Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microb Rev 2001;14:659-88.
- Aronson, N., Herwaldt, B.,et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016;63:e202-e264.
- Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016;16:584-91.
- Fletcher K, Issa R, Lockwood DN. Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the Hospital for Tropical Diseases, London. PLoS One 2015;10:e0121418.
- Blum J, Buffet P, Visser L, et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J Travel Med 2014;21:116-29.
- van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014;20:286-99.
- Reveiz L, Maia-Elkhoury ANS, Nicholls RS, Sierra Romero GA, Yadon ZE. Interventions for American cutaneous and mucocutaneous Leishmaniasis: a systematic review update. PLoS One 2013;8:e61843.
- Clarke CF, Bradley KK, Wright JH, Glowicz J. Emergence of autochthonous cutaneous leishmaniasis in northeastern Texas and southeastern Oklahoma. Am J Trop Med Hyg 2013;88:157-61.
- Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012;86:434-40.
- Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7:e35671.
- WHO. Control of the leishmaniases. World Health Organization technical report series 2010:xii-xiii, 1–186, back cover.
- Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561-77.
- Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
- Page last reviewed: October 15, 2018
- Page last updated: October 15, 2018
- Content source: